IRIS
PIERRI, IVANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.403
AS - Asia 26
SA - Sud America 9
NA - Nord America 2
Totale 9.440
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.403
CN - Cina 16
BR - Brasile 6
SG - Singapore 5
VN - Vietnam 5
EC - Ecuador 2
AR - Argentina 1
GT - Guatemala 1
MX - Messico 1
Totale 9.440
Salva come PNG Salva come JPEG
Città #
Genova 6.153
Genoa 1.895
Rapallo 763
Vado Ligure 572
Bordighera 20
Beijing 6
Ho Chi Minh City 3
Barretos 1
Bento Gonçalves 1
Espigão dOeste 1
Guatemala City 1
Guayaquil 1
Hanoi 1
Portovelo 1
Rio de Janeiro 1
Santa Bárbara 1
Uberaba 1
Vĩnh Tường 1
Álvaro Obregón 1
Totale 9.424
Salva come PNG Salva come JPEG
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 220
APO866 activity in hematologic malignancies: a preclinical in vitro study. 205
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112) 196
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 181
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 166
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 160
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 158
Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages 158
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 155
Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors 153
T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions. 152
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia 151
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 151
Circadian variations of autologous mixed lymphocyte reactions and endogenous cortisol. 151
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 149
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. 146
Thalidomide in agnogenic and secondary myelofibrosis 146
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 143
Analysis of the role of xenogeneic antigens in the proliferation of human T cells stimulated with autologous non-T cells and phytohemagglutinin-activated T cells. 142
Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA class II antigens and in autologous mixed lymphocyte reactions. 142
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 137
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 137
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 136
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 136
Evidence for killing of Mesenchymal Stem Cells (MSC) by autologous natural killer lymphocytes. 135
Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells 134
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 130
Human T lymphocytes in aging and malignancy: abnormalities in PHA-induced Ia antigen expression and in functional activity in autologous and allogeneic MLR. 128
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. 128
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 126
Acute tuberculous septicemia. 125
T-lymphocytes phenotype and functions in patients with head and neck cancer. 125
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 124
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 124
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 122
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. 120
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 119
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients 118
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 116
Essential Thrombocythemia: The Dermatologic Point of View 116
Deficiency of the autologous mixed lymphocyte reactions of non-T/T and T/T type in intravenous drug abusers infected by the human immunodeficiency virus (HIV). 115
In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand 113
Detection of platelet-associated antibodies by flow cytometry in hematological autoimmune disorders. 113
[Methods for studying pleiotropic drug resistance (multidrug resistance, MDR)]. 113
Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B 111
New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting. 110
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. 110
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 109
Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans. 109
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 108
Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin’s lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation 107
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 106
Lymphocytapheresis in the treatment of rheumatoid arthritis: clinical and immunological studies. 105
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. 104
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates pro-apoptotic signals in chronic lymphocytic leukemia B cells 103
Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. 102
PHA-T cells in systemic lupus erythematosus and in rheumatoid arthritis: abnormalities in HLA class II antigen induction and in autologous mixed lymphocyte reactions. 101
CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. 101
[Remarks on rupture of the heart in recent myocardial infarct]. 101
Plasmaexchange plus immunoglobulins for treatment of hypergammaglobulinaemic patients with AIDS and AIDS-related complex (ARC). 99
Human autologous mixed lymphocyte reactions (a review). 97
Role of normal adherent cells in the regulation of the autologous mixed lymphocyte reactions in humans. 95
In vitro enhancement of the proliferative response of human T cells to autologous non-T cells by hydralazine. 93
[Plasmacytoid lymphoma of the lung. Presentation of a case and review of the literature]. 92
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. 92
Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa 90
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. 89
Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. 88
Expression of HLA-class II antigens and proliferative capacity in autologous mixed lymphocyte reactions of human T lymphocytes exposed in vitro to alpha-endorphin. 87
CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells cdan be targeted with ligands to induce apoptosis 86
GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly. 83
Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method. 81
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 79
[Granulomatous giant-cell endometritis due to talc]. 79
Decreased sensitivity of T lymphocytes to normal adherent suppressor cells in patients with head and neck cancer. 75
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? 75
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. 72
Thiol containing antioxidant drugs and the human immune system. 69
Immunocompetence in lung cancer patients: analysis of serological and cellular parameters. 68
Totale 9.491
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.031
article - articoli 28.031
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021393 0 0 0 38 34 48 12 45 45 65 55 51
2021/2022943 27 73 48 111 30 60 77 206 34 88 36 153
2022/2023939 109 72 16 103 166 168 5 67 155 1 71 6
2023/2024485 27 62 8 51 45 111 24 23 20 7 30 77
2024/20251.344 19 106 41 78 210 151 111 206 40 69 152 161
2025/2026519 272 47 66 134 0 0 0 0 0 0 0 0
Totale 9.491